Analysts at Wedbush initiated coverage on Blueprint Medicines Corp BPMC with a Outperform rating.
The target price for Blueprint Medicines is set to $41.
Blueprint Medicines' shares rose 0.73 percent to $30.18 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
